| 摘要 |
<p>The present invention relates to new cytostatic composition comprising sub-cytostatic dosages of a first purine analog or a pharmaceutically acceptable salt thereof and a sub-cytostatic dosage of a second purine analog which is different to the first purine analog or a pharmaceutically acceptable salt thereof. The invention relates to the use of said cytostatic composition for treating leukemia, autoimmune diseases and inflammatory bowel disease.</p> |
